Clinical trial for Carcinoma, Non-Small-Cell Lung
Official title A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov ID: NCT06667076
What this study is testing
What is Amivantamab?
This is an investigational medicine being studied to treat a type of lung cancer called non-small cell lung cancer. It is designed to attach to specific proteins on cancer cells to help stop them from growing.
Also referred to as JNJ-61186372.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out how well the drug combinations work against the cancer.
- Who it's for
- Adults who have EGFR‑mutated locally advanced or metastatic non‑small cell lung cancer.
- What's involved
- Participants will receive amivantamab together with lazertinib or with platinum‑based chemotherapy, plus regular clinic visits and scans to check the cancer.
- Time commitment
- The trial lasts several months and requires multiple visits to the clinic for treatment and monitoring.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Have histologically or cytologically confirmed advanced or metastatic non-small cell lung cancer (NSCLC) that is not amenable to curative intent...
- Epidermal growth factor resistance-mutation (EGFRm) must be an Ex19del or Ex21 L858R substitution, as detected by food and drug administration...
- Have at least 1 measurable lesion, according to RECIST version (v)1.1, that has not been previously irradiated
- Any toxicities from prior systemic anticancer therapy must have resolved to national cancer institute common terminology criteria for adverse events...
- Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1
You likely can't join if
- Medical history of active interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis.
- Had major surgery excluding placement of vascular access or tumor biopsy or had significant traumatic injury within 4 weeks before the first dose of...
- Participant has uncontrolled tumor-related pain (symptomatic lesions amenable to palliative radiotherapy should be treated prior to first dosing)
- Received an investigational treatment that has not been cleared (based on at least 5 half lives of any pharmaceutical treatment) before the planned...
- Has a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment could likely interfere with any...
The study team makes the final eligibility decision.
Where it is enrolling
- Lancaster, California, United States
- Long Beach, California, United States
- South Pasadena, California, United States
- Upland, California, United States
- Hollywood, Florida, United States
- Pembroke Pines, Florida, United States
- Atlanta, Georgia, United States
- Zion, Illinois, United States
- Baltimore, Maryland, United States
- Kansas City, Missouri, United States
- Summit, New Jersey, United States
- Nashville, Tennessee, United States
- Dallas, Texas, United States
- Genk, Belgium
- Ghent, Belgium
- Leuven, Belgium
- Yvoir, Belgium
- Helsinki, Finland
- Oulu, Finland
- Turku, Finland
+ 44 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Lancaster, California, United States; Long Beach, California, United States; South Pasadena, California, United States; Upland, California, United States; Hollywood, Florida, United States; Pembroke Pines, Florida, United States and 58 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.